Barclays Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $14.00

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Rating) had its price objective raised by Barclays from $12.00 to $14.00 in a research note published on Friday, The Fly reports. Barclays currently has an equal weight rating on the biotechnology company’s stock.

Several other brokerages also recently commented on BCRX. Oppenheimer dropped their price target on BioCryst Pharmaceuticals from $16.00 to $13.00 and set an outperform rating on the stock in a research report on Friday, May 13th. Piper Sandler cut their target price on shares of BioCryst Pharmaceuticals from $24.00 to $19.00 in a research note on Thursday, May 5th. Royal Bank of Canada decreased their price target on shares of BioCryst Pharmaceuticals from $16.00 to $14.00 and set a sector perform rating on the stock in a research report on Tuesday, April 12th. Cantor Fitzgerald reiterated an overweight rating on shares of BioCryst Pharmaceuticals in a research note on Monday, May 9th. Finally, Evercore ISI lowered their price target on BioCryst Pharmaceuticals from $25.00 to $15.00 in a research note on Friday, April 8th. Eight equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of Hold and an average target price of $17.78.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $14.05 on Friday. The stock’s 50 day simple moving average is $10.79 and its 200 day simple moving average is $12.78. BioCryst Pharmaceuticals has a twelve month low of $7.61 and a twelve month high of $19.99. The company has a market capitalization of $2.61 billion, a price-to-earnings ratio of -12.22 and a beta of 2.20.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. During the same quarter last year, the firm earned ($0.24) earnings per share. On average, analysts forecast that BioCryst Pharmaceuticals will post -1.34 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Semmax Financial Advisors Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 389.6% during the first quarter. Semmax Financial Advisors Inc. now owns 1,699 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,352 shares in the last quarter. Strs Ohio acquired a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at $32,000. Fairfield Bush & CO. bought a new position in BioCryst Pharmaceuticals in the 1st quarter valued at $34,000. CWM LLC acquired a new position in BioCryst Pharmaceuticals in the fourth quarter worth $47,000. Finally, Lazard Asset Management LLC bought a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $57,000. 63.86% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

(Get Rating)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Featured Stories

The Fly logo

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.